Drug-drug interactions in pharmacologic management of gastroparesis

Neurogastroenterology and Motility

Volumn 27, Issue 11, 2015, Pages 1528-1541

  Youssef, A S ^a,c   Parkman, H P ^b   Nagar, S ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PKPD Bioscience   (United States)

Author keywords

Adverse drug reactions; Domperidone; Drug drug interaction; Gastroparesis; Metoclopramide; Prokinetic agent

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTIDIABETIC AGENT; ANTIEMETIC AGENT; BETHANECHOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; CISAPRIDE; CYCLOSPORIN; DIAZEPAM; DIGESTIVE TRACT AGENT; DOLASETRON MESILATE; DOMPERIDONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; GABAPENTIN; GHRELIN RECEPTOR AGONIST; GRANISETRON; METOCLOPRAMIDE; MOTILIN RECEPTOR AGONIST; ONDANSETRON; PHENOTHIAZINE DERIVATIVE; PHYSOSTIGMINE; PROCHLORPERAZINE; PROKINETIC AGENT; PROMETHAZINE; RANITIDINE; SEROTONIN 4 AGONIST; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; GASTROINTESTINAL AGENT;

COMBINATION CHEMOTHERAPY; DIABETIC PATIENT; DRUG CONTRAINDICATION; DRUG DRUG INTERACTION; DRUG INTERACTION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; NAUSEA AND VOMITING; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STOMACH PARESIS; TREATMENT PLANNING; ADVERSE DRUG REACTION; ADVERSE EFFECTS; COMBINATION DRUG THERAPY; GASTROPARESIS;

DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GASTROINTESTINAL AGENTS; GASTROPARESIS; HUMANS;

EID: 84945446807     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12614     Document Type: Review

References (122)

1. Masaoka T, Tack J. Gastroparesis: current concepts and management. Gut Liv 2009; 3: 166-73.
2. Stapleton J, Wo JM. Current treatment of nausea and vomiting associated with gastroparesis: antiemetics, prokinetics, tricyclics. Gastrointest Endosc Clin N Am 2009; 19: 57-72.
3. Abell TL, Bernstein RK, Cutts T, Farrugia G, Forster J, Hasler WL, McCallum RW, Olden KW et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil 2006; 18: 263-83.
4. Lyrenås EB, Olsson EH, Arvidsson UC, Orn TJ, Spjuth JH. Prevalence and determinants of solid and liquid gastric emptying in unstable type I diabetes. Relationship to postprandial blood glucose concentrations. Diabetes Care 1997; 20: 413-8.
5. Horowitz M, Harding PE, Maddox AF, Wishart JM, Akkermans LM, Chatterton BE, Shearman DJ. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989; 32: 151-9.
6. Choung RS, Locke GR, Schleck CD, Zinsmeister AR, Melton LJ, Talley NJ. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol 2012; 107: 82-8.
7. Grover M, Farrugia G, Lurken MS, Bernard CE, Faussone-Pellegrini MS, Smyrk TC, Parkman HP, Abell TL et al. Cellular changes in diabetic and idiopathic gastroparesis. Gastroenterology 2011; 140: 1575-85.
8. Goodman LS, Hardman JG, Limbird LE, Gilman AG. Goodman and Gilman's the pharmacological basis of therapeutics, 10th edn. New York: McGraw-Hill, 2001.
9. Revicki DA, Camilleri M, Kuo B, Szarka LA, McCormack J, Parkman HP. Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Index-Daily Diary (GCSI-DD). Neurogastroenterol Motil 2012; 24: 456-63.
10. McPhee SJ, Hammer GD. Pathophysiology of Disease an Introduction to Clinical Medicine, 6th edn. New York: McGraw-Hill Medical, 2009.
11. He CL, Soffer EE, Ferris CD, Walsh RM, Szurszewski JH, Farrugia G. Loss of interstitial cells of Cajal and inhibitory innervation in insulin-dependent diabetes. Gastroenterology 2001; 121: 427-34.
12. Zárate N, Mearin F, Wang XY, Hewlett B, Huizinga JD, Malagelada JR. Severe idiopathic gastroparesis due to neuronal and interstitial cells of Cajal degeneration: pathological findings and management. Gut 2003; 52: 966-70.
13. Harberson J, Thomas RM, Harbison SP, Parkman HP. Gastric neuromuscular pathology in gastroparesis: analysis of full-thickness antral biopsies. Dig Dis Sci 2010; 55: 359-70.
14. Friedenberg F, Parkman H. Delayed gastric emptying: whom to test, how to test, and what to do. Curr Treat Options Gastroenterol 2006; 9: 295-304.
15. Haans J, Masclee A. Review article: the diagnosis and management of gastroparesis. Aliment Pharmacol Ther 2007; 26(Suppl. 2): 37-46.
16. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-5.
17. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-9.
18. Atkin PA, Veitch PC, Veitch EM, Ogle SJ. The epidemiology of serious adverse drug reactions among the elderly. Drugs Aging 1999; 14: 141-52.
19. Passarelli MC, Jacob-Filho W, Figueras A. Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. Drugs Aging 2005; 22: 767-77.
20. Evans G. A handbook of bioanalysis and drug metabolism. Boca Raton, CA: CRC Press, 2004.
21. Wang JF, Chou KC. Molecular modeling of cytochrome P450 and drug metabolism. Curr Drug Metab 2010; 11: 342-6.
22. Meinertz T. Mibefradil - a drug which may enhance the propensity for the development of abnormal QT prolongation. European Heart Journal Supplements 2001; 3: K89-92.
23. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002; 36: 288-95.
24. Vazquez E, Whitfield L. Seldane warnings. Posit Aware 1997; 8: 12.
25. Mayhew B, Jones D, Hall S. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 2000; 28: 1031-7.
26. Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother 1999; 33: 429-40.
27. Reddymasu S, Soykan I, McCallum R. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 2007; 102: 2036-45.
28. Argikar U, Gomez J, Ung D, Parkman H, Nagar S. Identification of novel metoclopramide metabolites in humans: in vitro and in vivo studies. Drug Metab Dispos 2010; 38: 1295-307.
29. Teng L, Bruce R, Dunning L. Metoclopramide metabolism and determination by high-pressure liquid chromatography. J Pharm Sci 1977; 66: 1615-8.
30. Shaffer D, Butterfield M, Pamer C, Mackey AC. Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J Am Pharm Assoc (2003) 2004; 44: 661-5.
31. Food and Drug Administration. Press Announcements - FDA Requires Boxed Warning and Risk Mitigation Strategy for Metoclopramide-Containing Drugs. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149533.htm (accessed March 06, 2015).
32. Food and Drug Administration. Reglan Tablets (Metoclopramide Tablets, USP) Safety Information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/017854s052lbl.pdf (accessed March 06, 2015).
33. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 2010; 31: 11-9.
34. Jolliet P, Nion S, Allain-Veyrac G, Tilloy-Fenart L, Vanuxeem D, Berezowski V, Cecchelli R. Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared to domperidone, metoclopramide and chlorpromazine, using an in vitro model of the blood-brain barrier. Pharmacol Res 2007; 56: 11-7.
35. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517-24.
36. Osborne RJ, Slevin ML, Hunter RW, Hamer J. Cardiotoxicity of intravenous domperidone. Lancet 1985; 2: 385.
37. Roussak JB, Carey P, Parry H. Cardiac arrest after treatment with intravenous domperidone. Br Med J (Clin Res Ed) 1984; 289: 1579.
38. Ahmad N, Keith-Ferris J, Gooden E, Abell T. Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol 2006; 6: 571-6.
39. Hondeghem LM. Domperidone: limited benefits with significant risk for sudden cardiac death. J Cardiovasc Pharmacol 2013; 61: 218-25.
40. Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet 1981; 6: 61-70.
41. Meuldermans W, Hurkmans R, Swysen E, Hendrickx J, Michiels M, Lauwers W, Heykants J. On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man. Eur J Drug Metab Pharmacokinet 1981; 6: 49-60.
42. Agarwal S, Gowda KV, Mandal U, Ghosh D, Bose A, Sarkar AK, Chattaraj TK, Pal TK. Bioequivalence study of a sustained release fixed dose combination capsule containing esomeprazole and domperidone in healthy subjects. Arzneimittelforschung 2007; 57: 274-7.
43. Wang R, Newton D, Scheri T, Lu A. Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. Drug Metab Dispos 1997; 25: 502-7.
44. Okudaira T, Kotegawa T, Imai H, Tsutsumi K, Nakano S, Ohashi K. Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. J Clin Pharmacol 2007; 47: 871-6.
45. Food and Drug Administration. Erythromycin ethylsuccinate safety information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050207s071lbl.pdf (accessed March 06, 2015).
46. Abrahamsson H. Severe gastroparesis: new treatment alternatives. Best Pract Res Clin Gastroenterol 2007; 21: 645-55.
47. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351: 1089-96.
48. Larson JM, Tavakkoli A, Drane WE, Toskes PP, Moshiree B. Advantages of azithromycin over erythromycin in improving the gastric emptying half-time in adult patients with gastroparesis. J Neurogastroenterol Motil 2010; 16: 407-13.
49. Moshiree B, McDonald R, Hou W, Toskes PP. Comparison of the effect of azithromycin versus erythromycin on antroduodenal pressure profiles of patients with chronic functional gastrointestinal pain and gastroparesis. Dig Dis Sci 2010; 55: 675-83.
50. Sanger GJ, Westaway SM, Barnes AA, Macpherson DT, Muir AI, Jarvie EM, Bolton VN, Cellek S et al. GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterol Motil 2009; 21: 657-64, e630-651.
51. Ozaki K, Monnai M, Onoma M, Muramatsu H, Yogo K, Watanabe T, Oda Y, Katagiri K et al. Effects of mitemcinal (GM-611), an orally active erythromycin-derived prokinetic agent, on delayed gastric emptying and postprandial glucose in a new minipig model of diabetes. J Diabetes Complications 2008; 22: 339-47.
52. Food and Drug Administration. Propulsid (cisapride) Dear Healthcare Professional Letter Apr 2000. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm175000.htm (accessed March 06, 2015).
53. Vickers AE, Zollinger M, Dannecker R, Tynes R, Heitz F, Fischer V. In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos 2001; 29: 1269-76.
54. Food and Drug Administration. FDA Announces Discontinued Marketing of GI Drug, Zelnorm, for Safety Reasons. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108879.htm (accessed March 06, 2015).
55. Manabe N, Wong BS, Camilleri M. New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders. Expert Opin Investig Drugs 2010; 19: 765-75.
56. Camilleri M. Novel therapeutic agents in neurogastroenterology: advances in the past year. Neurogastroenterol Motil 2014; 26: 1070-8.
57. Ejskjaer N, Wo JM, Esfandyari T, Mazen Jamal M, Dimcevski G, Tarnow L, Malik RA, Hellström PM et al. A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 2013; 25: e140-50.
58. McCallum RW, Lembo A, Esfandyari T, Bhandari BR, Ejskjaer N, Cosentino C, Helton N, Mondou E et al. Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 2013; 25: e705-17.
59. Shin A, Camilleri M, Busciglio I, Burton D, Smith SA, Vella A, Ryks M, Rhoten D et al. The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus. Clin Gastroenterol Hepatol 2013; 11: 1453-1459.e4.
60. Shin A, Camilleri M, Busciglio I, Burton D, Stoner E, Noonan P, Gottesdiener K, Smith SA et al. Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care 2013; 36: 41-8.
61. Parkman HP, Trate DM, Knight LC, Brown KL, Maurer AH, Fisher RS. Cholinergic effects on human gastric motility. Gut 1999; 45: 346-54.
62. Hoogerwerf WA, Pasricha PJ, Kalloo AN, Schuster MM. Pain: the overlooked symptom in gastroparesis. Am J Gastroenterol 1999; 94: 1029-33.
63. Cherian D, Sachdeva P, Fisher RS, Parkman HP. Abdominal pain is a frequent symptom of gastroparesis. Clin Gastroenterol Hepatol 2010; 8: 676-81.
64. Parkman H, Fass R, Foxx-Orenstein A. Treatment of patients with diabetic gastroparesis. Gastroenterol Hepatol (N Y) 2010; 6: 1-16.
65. Waseem S, Moshiree B, Draganov PV. Gastroparesis: current diagnostic challenges and management considerations. World J Gastroenterol 2009; 15: 25-37.
66. Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol 2008; 103: 416-23.
67. Wadhwa NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplant Proc 1987; 19: 1730-3.
68. Gamble JA, Gaston JH, Nair SG, Dundee JW. Some pharmacological factors influencing the absorption of diazepam following oral administration. Br J Anaesth 1976; 48: 1181-5.
69. Lee HT, Lee YJ, Chung SJ, Shim CK. Effect of prokinetic agents, cisapride and metoclopramide, on the bioavailability in humans and intestinal permeability in rats of ranitidine, and intestinal charcoal transit in rats. Res Commun Mol Pathol Pharmacol 2000; 108: 311-23.
70. Morris JG, Parsons RL, Trounce JR, Groves MJ. Plasma dopa concentrations after different preparations of levodopa in normal subjects. Br J Clin Pharmacol 1976; 3: 983-90.
71. Johnson BF, Bustrack JA, Urbach DR, Hull JH, Marwaha R. Effect of metoclopramide on digoxin absorption from tablets and capsules. Clin Pharmacol Ther 1984; 36: 724-30.
72. Marathe CS, Rayner CK, Jones KL, Horowitz M. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp Diabetes Res 2011; 2011: 279530.
73. Delgado-Aros S, Kim DY, Burton DD, Thomforde GM, Stephens D, Brinkmann BH, Vella A, Camilleri M. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol 2002; 282: G424-31.
74. Pearson PG, Wienkers LC. Handbook of Drug Metabolism, 2nd edn. New York: Informa Healthcare USA, 2009.
75. Orr ST, Ripp SL, Ballard TE, Henderson JL, Scott DO, Obach RS, Sun H, Kalgutkar AS. Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. J Med Chem 2012; 55: 4896-933.
76. Desta Z, Soukhova N, Mahal SK, Flockhart DA. Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos 2000; 28: 789-800.
77. van Haarst AD, van 't Klooster GA, van Gerven JM, Schoemaker RC, van Oene JC, Burggraaf J, Coene MC, Cohen AF. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 1998; 64: 542-6.
78. Sekkarie MA. Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. Am J Kidney Dis 1997; 30: 437-9.
79. Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001; 96: 1698-703.
80. Brown H, Ito K, Galetin A, Houston J. Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 2005; 60: 508-18.
81. Galetin A, Gertz M, Houston J. Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions. Drug Metab Pharmacokinet 2010; 25: 28-47.
82. Rodrigues AD. Drug-drug Interactions. New York: Informa Healthcare USA, 2008.
83. Rogers JF, Nafziger AN, Bertino JS. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 2002; 113: 746-50.
84. Desta Z, Wu G, Morocho A, Flockhart D. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos 2002; 30: 336-43.
85. Fischer V, Vickers A, Heitz F, Mahadevan S, Baldeck J, Minery P, Tynes R. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 1994; 22: 269-74.
86. Nakamura K, Yokoi T, Inoue K, Shimada N, Ohashi N, Kume T, Kamataki T. CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes. Pharmacogenetics 1996; 6: 449-57.
87. Collins JM, Finn AL, Voyksner RD, Lindley CM. In-vitro characterization of the metabolism of prochlorperazine. Clin Pharmacol Ther 2004; 75: P85-P85.
88. Vlase L, Leucuta A, Farcau D, Nanulescu M. Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. Biopharm Drug Dispos 2006; 27: 285-9.
89. Hara Y, Nakajima M, Miyamoto KI, Yokoi T. Inhibitory effects of psychotropic drugs on mexiletine metabolism in human liver microsomes: prediction of in vivo drug interactions. Xenobiotica 2005; 35: 549-60.
90. Fisher AA, Davis MW. Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. Ann Pharmacother 2002; 36: 67-71.
91. Drolet B, Rousseau G, Daleau P, Cardinal R, Turgeon J. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 2000; 102: 1883-5.
92. Simard C, Michaud V, Gibbs B, Massé R, Lessard E, Turgeon J. Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica 2004; 34: 1013-23.
93. Ward B, Morocho A, Kandil A, Galinsky R, Flockhart D, Desta Z. Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol 2004; 58: 277-87.
94. Youssef AS, Argikar UA, Pathikonda M, Parkman HP, Nagar S. Identification of domperidone metabolites in plasma and urine of gastroparesis patients with LC-ESI-MS/MS. Xenobiotica 2013; 43: 1073-83.
95. Ung D, Parkman H, Nagar S. Metabolic interactions between prokinetic agents domperidone and erythromycin: an in vitro analysis. Xenobiotica 2009; 39: 749-56.
96. Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005; 44: 279-304.
97. Food and Drug Administration. Draft guidance for industry. Drug interaction studies - study design, data analysis, and implications for dosing and labeling recommendations. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf (accessed March 06, 2015).
98. Sahi J, Black C, Hamilton G, Zheng X, Jolley S, Rose K, Gilbert D, LeCluyse E et al. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos 2003; 31: 439-46.
99. Choi J, Burm J. Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats. Arch Pharm Res 2008; 31: 1200-4.
100. Lim H, Duczak NJ, Brougham L, Elliot M, Patel K, Chan K. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. Drug Metab Dispos 2005; 33: 1211-9.
101. Youssef AS, Parkman HP, Nagar S. Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism in vitro. Xenobiotica 2014; 44: 792-803.
102. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011; 50: 81-98.
103. Dixon C, Colthup P, Serabjit-Singh C, Kerr B, Boehlert C, Park G, Tarbit M. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 1995; 23: 1225-30.
104. Villikka K, Kivistö K, Neuvonen P. The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. Clin Pharmacol Ther 1999; 65: 377-81.
105. Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol 2012; 73: 411-21.
106. Yoshizato T, Kotegawa T, Imai H, Tsutsumi K, Imanaga J, Ohyama T, Ohashi K. Itraconazole and domperidone: a placebo-controlled drug interaction study. Eur J Clin Pharmacol 2012; 68: 1287-94.
107. Mishra H, Polak S, Jamei M, Rostami-Hodjegan A. Interaction between domperidone and ketoconazole: toward prediction of consequent QTc prolongation using purely in vitro information. CPT Pharmacometrics Syst Pharmacol 2014; 3: e130.
108. Chang SY, Fancher RM, Zhang H, Gan J. Mechanism-based inhibition of human cytochrome P4503A4 by domperidone. Xenobiotica 2010; 40: 138-45.
109. Niwa T, Yamamoto S, Saito M, Kobayashi N, Ikeda K, Noda Y, Takagi A. Effects of serotonin-3 receptor antagonists on cytochrome P450 activities in human liver microsomes. Biol Pharm Bull 2006; 29: 1931-5.
110. Bertschy G, Vandel S, Vandel B, Allers G, Volmat R. Fluvoxamine-tricyclic antidepressant interaction. An accidental finding. Eur J Clin Pharmacol 1991; 40: 119-20.
111. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol 1998; 38: 112-21.
112. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525-38.
113. Ghahramani P, Ellis SW, Lennard MS, Ramsay LE, Tucker GT. Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol 1997; 43: 137-44.
114. Olesen OV, Linnet K. Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes. Pharmacology 1997; 55: 235-43.
115. Brøsen K. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Clin Pharmacokinet 1995; 29(Suppl. 1): 20-5.
116. Koyama E, Chiba K, Tani M, Ishizaki T. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther 1997; 281: 1199-210.
117. Brøsen K, Zeugin T, Meyer UA. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin Pharmacol Ther 1991; 49: 609-17.
118. Dahl ML, Iselius L, Alm C, Svensson JO, Lee D, Johansson I, Ingelman-Sundberg M, Sjöqvist F. Polymorphic 2-hydroxylation of desipramine. A population and family study. Eur J Clin Pharmacol 1993; 44: 445-50.
119. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994; 268: 1278-83.
120. Olesen OV, Linnet K. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos 1997; 25: 740-4.
121. Jaakkola T, Laitila J, Neuvonen P, Backman J. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol 2006; 99: 44-51.
122. Kajosaari L, Jaakkola T, Neuvonen P, Backman J. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. Eur J Clin Pharmacol 2006; 62: 217-23.